CN102872150B - Application of Houttuynoid B in medicament for treating prostatic cancer - Google Patents
Application of Houttuynoid B in medicament for treating prostatic cancer Download PDFInfo
- Publication number
- CN102872150B CN102872150B CN 201210419695 CN201210419695A CN102872150B CN 102872150 B CN102872150 B CN 102872150B CN 201210419695 CN201210419695 CN 201210419695 CN 201210419695 A CN201210419695 A CN 201210419695A CN 102872150 B CN102872150 B CN 102872150B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- prostatic cancer
- application
- medicament
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of Houttuynoid B in a medicament for treating prostatic cancer, and belongs to the technical field of new application of medicaments. In-vitro methyl thiazolyl tetrazolium (MTT) anti-tumor activity evaluation shows that the Houttuynoid B has a remarkable inhibiting effect on growth of human prostatic cancer cell lines ALVA, gpc-1, 9L-B and Du145. Therefore, the Houttuynoid B can be used for preparing the prostatic cancer resistant medicament, and has a good development and application prospect. The invention discloses the application of the Houttuynoid Bin preparation of the medicament for treating the prostatic cancer for the first time, the skeleton type belongs to a brand-new skeleton type, and the Houttuynoid B has unexpected strong inhibiting activity on prostatic cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid B, relate in particular to the application of Houttuynoid B in the preparation antiprostate cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid B that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid B that the present invention relates in preparation treatment carcinoma of prostate medicine, because framework types belongs to brand-new framework types, and its inhibition for prostate gland cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of prostate obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid B in the preparation antiprostate cancer, and the structural formula of Houttuynoid B is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid B also has significant inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 0.19 ± 0.03 μ M, 0.11 ± 0.06 μ M, 0.52 ± 0.05 μ M and 0.59 ± 0.06 μ M.Therefore, Houttuynoid B can for the preparation of antiprostate cancer, have good development prospect.
The purposes of the Houttuynoid B that the present invention relates in preparation treatment carcinoma of prostate medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for prostate gland cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of prostate obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid B involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid B tablet involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid B capsule involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid B to the growth inhibited effect of human prostate cancer cell line
1. method: the cell that is in the growth logarithmic (log) phase: human prostate cancer cell line ALVA, gpc-1,9L-B and Du145(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid B has significant inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145.This chemical compound suppresses the IC of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145 growth
50Value is respectively: 0.19 ± 0.03 μ M, 0.11 ± 0.06 μ M, 0.52 ± 0.05 μ M and 0.59 ± 0.06 μ M.
Shown that by above-described embodiment Houttuynoid B of the present invention has good inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145.Prove that thus Houttuynoid B of the present invention has the anti-prostate cancer activity, can be for the preparation of antiprostate cancer.
Claims (1)
1.Houttuynoid the application of B in preparation treatment carcinoma of prostate medicine, described compound H outtuynoid B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419695 CN102872150B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating prostatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419695 CN102872150B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating prostatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872150A CN102872150A (en) | 2013-01-16 |
| CN102872150B true CN102872150B (en) | 2013-10-23 |
Family
ID=47473821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210419695 Expired - Fee Related CN102872150B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating prostatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872150B (en) |
-
2012
- 2012-10-27 CN CN 201210419695 patent/CN102872150B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen et al.;《ORGANIC LETTERS》;20120313;第14卷(第7期);第1772-1775页 * |
| Shao-DanChenetal..HouttuynoidsA-E Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《ORGANIC LETTERS》.2012 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872150A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872150B (en) | Application of Houttuynoid B in medicament for treating prostatic cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872149B (en) | Application of Houttuynoid B in medicament for treating cecum cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872086A (en) | Application of Houttuynoid A in medicines for treating skin cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102895249A (en) | Application of Houttuynoid E to medicament for treating prostatic carcinoma | |
| CN102872151A (en) | Application of Houttuynoid B in medicament for treating nasopharyngeal cancer | |
| CN102872088A (en) | Application of Houttuynoid D in medicines for treating nasopharyngeal carcinoma | |
| CN102885843A (en) | Application of Houttuynoid B in medicament for treating breast cancer | |
| CN102872085A (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102861048A (en) | Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102861052A (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861051A (en) | Application of Houttuynoid A in medicine for treating renal cancer | |
| CN102895248A (en) | Application of Houttuynoid A in drugs for treating laryngocarcinoma | |
| CN102872072A (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102895247A (en) | Application of Houttuynoid B to medicament for treating oophoroma | |
| CN102872139A (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: FENG MINGSHAN Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141208 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141208 Address after: 226400 No. three, No. 41, Haihe Beach village, Yuan Zhen, Jiangsu County, Rudong Patentee after: Feng Mingshan Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131023 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |